Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

CNW/ - Medcan, a global leader in proactive health and wellness, announced the Canadian launch of the Galleri® multi-cancer ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk ...

IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer Basel, 20 October 2025 - Roche (SIX: RO, ROG; ...

Researchers found that pembrolizumab, an immune-activating cancer drug, lowered the risk of distant metastases in patients ...

After surviving three types of cancer and having to face the harsh realities of colorectal and endometrial cancer and basal ...

And that's a good thing. Oxidants can damage the structure and function of the chemicals in your body critical to life—like ...

Elevated early-onset cancer incidence is accompanied by similar increases in older adults as well, and that rising obesity ...